Table 1. Efficiency of predicting supertype binding by prototype allele algorithms.
Percent of supertype binders
predicted*
|
|||||||
---|---|---|---|---|---|---|---|
Source | Refs. | A2 | A11 | B7 | A1 | A24 | DR1 |
HCV | 15, 21† | 88 (15 of 17)‡ | 71 (10 of 14) | 0 (0 of 2) | 50 (3 of 6) | 40 (2 of 5) | 100 (6 of 6) |
P. falciparum§ | 15, 22, 23† | 82 (9 of 11) | 86 (6 of 7) | 0 (0 of 1) | 67 (2 of 3) | 78 (7 of 9) | 78 (7 of 9) |
Mage2/3 | 15, 26† | 57 (8 of 14) | 100 (6 of 6) | 100 (4 of 4) | 80 (4 of 5) | 0 (0 of 1) | 100 (3 of 3) |
HBV | 15, 25† | 63 (12 of 19) | 50 (6 of 12) | 75 (6 of 8) | 78 (7 of 9) | 65 (11 of 17) | 92 (11 of 12) |
Total | 72 (44 of 61) | 72 (28 of 39) | 67 (10 of 15) | 70 (16 of 23) | 63 (20 of 32) | 90 (27 of 30) |
A supertype binder is a peptide with the capacity to bind ≥50% of the MHC molecules in a given supertype.
J.S. and A.S., unpublished observations.
The numbers in parentheses indicate the number of supertype binders identified by the respective algorithm versus the total number of source-derived supertype binders.
Supertype peptides derived from the four previously well characterized P. falciparum antigens (PfCSP, PfSSP2, PfLSA, and PfEXP1).